Janae' Richard
Cardiovascular Disease · Dallas, TXNPI 1215381165
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 69.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $8,119 and has fallen 90.0% since, to $814 in 2025.
Across 107 payments — averaging $101.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$7K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$588
- Abiomed$558
- Sanofi-aventis U.S. LLC$268
- Pfizer$236
- Novartis$220
- plus $1K from 19 others
What the payments were for
- Consulting fees$6,02056%
- Travel & lodging$9929%
- Food & beverage$3,80335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 12 | $7,498 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $588 |
| Abiomed | 7 | $558 |
| Sanofi-aventis U.S. LLC | 3 | $268 |
| Pfizer | 9 | $236 |
| Novartis | 6 | $220 |
| Merck | 10 | $189 |
| Medtronic | 3 | $161 |
| Biosense Webster, Inc. | 2 | $129 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 5 | $122 |
| AstraZeneca | 9 | $121 |
| E.r. Squibb & Sons, L.L.C. | 6 | $113 |
| Kestra Medical Technology Services, Inc. | 3 | $94 |
| Itamar Medical Inc | 1 | $86 |
| Atricure, Inc. | 1 | $84 |
| Abbott | 1 | $55 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Boston Scientific | 1 | $26 |
| Novo Nordisk | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$6,176
- Impella$419
- INJECTAFER$125
- Carto 3$124
How this compares
$10,815 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol | 11 | $77 |
| Lisinopril | 11 | $75 |
| Spironolactone | 17 | $69 |
| Metoprolol Succinate | 11 | $54 |
| Atorvastatin Calcium | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Dallas
- Ramin Farzaneh-FarDallas$17.1M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Ambarish PandeyDallas$325K
- Eric PetersonDallas$187K
- Brittany WeberDallas$186K
- James de LemosDallas$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.